These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27593107)

  • 21. Prognostic value of fluorine-18 fluorodeoxyglucose positron-emission tomography imaging in patients with head and neck squamous cell carcinoma.
    Querellou S; Abgral R; Le Roux PY; Nowak E; Valette G; Potard G; Le Duc-Pennec A; Cavarec MB; Marianovski R; Salaün PY
    Head Neck; 2012 Apr; 34(4):462-8. PubMed ID: 21604320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.
    Tachibana I; Nishimura Y; Shibata T; Kanamori S; Nakamatsu K; Koike R; Nishikawa T; Ishikawa K; Tamura M; Hosono M
    J Radiat Res; 2013 Nov; 54(6):1078-84. PubMed ID: 23589026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
    Komar G; Lehtiö K; Seppänen M; Eskola O; Levola H; Lindholm P; Sipilä H; Seppälä J; Grénman R; Solin O; Minn H
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2042-50. PubMed ID: 24898846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.
    Marcus C; Ciarallo A; Tahari AK; Mena E; Koch W; Wahl RL; Kiess AP; Kang H; Subramaniam RM
    J Nucl Med; 2014 Sep; 55(9):1411-6. PubMed ID: 24947059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.
    Trinkaus ME; Hicks RJ; Young RJ; Peters LJ; Solomon B; Bressel M; Corry J; Fisher R; Binns D; McArthur GA; Rischin D
    J Med Imaging Radiat Oncol; 2014 Feb; 58(1):89-97. PubMed ID: 24529061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.
    Bekaert L; Valable S; Lechapt-Zalcman E; Ponte K; Collet S; Constans JM; Levallet G; Bordji K; Petit E; Branger P; Emery E; Manrique A; Barré L; Bernaudin M; Guillamo JS
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1383-1392. PubMed ID: 28315948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.
    Kazmierska J; Cholewinski W; Piotrowski T; Sowinska A; Bak B; Cegła P; Malicki J
    Br J Radiol; 2020 Feb; 93(1106):20180781. PubMed ID: 31860336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
    Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
    Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of 18F-FDG PET in patients with head and neck squamous cell cancer.
    Torizuka T; Tanizaki Y; Kanno T; Futatsubashi M; Naitou K; Ueda Y; Ouchi Y
    AJR Am J Roentgenol; 2009 Apr; 192(4):W156-60. PubMed ID: 19304675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diffusion-Weighted MRI in the Assessment of Early Treatment Response in Patients with Squamous-Cell Carcinoma of the Head and Neck: Comparison with Morphological and PET/CT Findings.
    Martins EB; Chojniak R; Kowalski LP; Nicolau UR; Lima EN; Bitencourt AG
    PLoS One; 2015; 10(11):e0140009. PubMed ID: 26562784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma.
    de Galiza Barbosa F; Riesterer O; Tanadini-Lang S; Stieb S; Studer G; Pruschy M; Huber GF; Huellner MW; Stolzmann P; Veit-Haibach P
    Head Neck; 2020 Feb; 42(2):163-170. PubMed ID: 31705729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of CT and ¹⁸F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy.
    Inohara H; Enomoto K; Tomiyama Y; Yoshii T; Osaki Y; Higuchi I; Inoue T; Hatazawa J
    Acta Otolaryngol; 2009 Aug; 129(8):893-9. PubMed ID: 18839385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.